Pediatric Hypertrophic Cardiomyopathy Differential Diagnoses

1. Lipshultz SE, Orav EJ, Wilkinson JD, et al, for the Pediatric Cardiomyopathy Registry Study Group. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013 Dec 7. 382 (9908):1889-97. [Medline].

2. El-Saiedi SA, Seliem ZS, Esmail RI. Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients. Cardiol Young. 2014 Aug. 24 (4):702-8. [Medline].

3. Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002 Apr. 109 (8):1013-20. [Medline]. [Full Text].

4. Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989 Nov 16. 321 (20):1372-8. [Medline].

5. Sabater-Molina M, Perez-Sanchez I, Hernandez Del Rincon JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: a review of current state. Clin Genet. 2017 Apr 3. [Medline].

6. Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012 Sep. 164 (3):442-8. [Medline].

7. Hindieh W, Adler A, Weissler-Snir A, Fourey D, Harris S, Rakowski H. Exercise in patients with hypertrophic cardiomyopathy: A review of current evidence, national guideline recommendations and a proposal for a new direction to fitness. J Sci Med Sport. 2017 Apr. 20 (4):333-8. [Medline].

8. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007 Feb 13. 115 (6):773-81. [Medline].

9. Ziolkowska L, Turska-Kmiec A, Petryka J, Kawalec W. Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatr Cardiol. 2016 Mar. 37 (3):448-58. [Medline].

10. McCaffrey FM, Braden DS, Strong WB. Sudden cardiac death in young athletes. A review. Am J Dis Child. 1991 Feb. 145 (2):177-83. [Medline].

11. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996 Jul 17. 276 (3):199-204. [Medline].

12. Rao PS. Prevention of sudden death in athletes. Pediat Therapeut. 2015 Aug 20. 5:e129. [Full Text].

13. Maron BJ, Spirito P, Ackerman MJ, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Apr 9. 61 (14):1527-35. [Medline].

14. Bolin E, Lam W. A review of sensitivity, specificity, and likelihood ratios: evaluating the utility of the electrocardiogram as a screening tool in hypertrophic cardiomyopathy. Congenit Heart Dis. 2013 Sep-Oct. 8 (5):406-10. [Medline].

15. [Guideline] Gersh BJ, Maron BJ, Bonow RO, et al, for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Tho... J Am Coll Cardiol. 2011 Dec 13. 58 (25):e212-60. [Medline].

16. Jay A, Chikarmane R, Poulik J, Misra VK. Infantile hypertrophic cardiomyopathy associated with a novel MYL3 mutation. Cardiology. 2013. 124 (4):248-51. [Medline].

17. Cortez D, Sharma N, Cavanaugh J, et al. The spatial QRS-T angle outperforms the Italian and Seattle ECG-based criteria for detection of hypertrophic cardiomyopathy in pediatric patients. J Electrocardiol. 2015 Sep-Oct. 48 (5):826-33. [Medline].

18. Fulton N, Rajiah P. Utility of magnetic resonance imaging in the evaluation of left ventricular thickening. Insights Imaging. 2017 Apr. 8 (2):279-93. [Medline].

19. Guerrero I, Dhoble A, Fasulo M, et al. Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2016 Nov 15. 88 (6):971-7. [Medline].

20. [Guideline] Elliott PM, Anastasakis A, Borger MA, et al, for the authors/task force members. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14. 35 (39):2733-79. [Medline].

21. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm. 2005 Aug. 2 (8):814-9. [Medline].

22. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008 Apr 29. 51 (17):1685-91. [Medline].

23. Kaski JP, Tome Esteban MT, Lowe M, Set al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart. 2007 Mar. 93 (3):372-4. [Medline]. [Full Text].

24. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007 Jul 25. 298 (4):405-12. [Medline].

25. [Guideline] Epstein AE, DiMarco JP, Ellenbogen KA, et al, for the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices), AATS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 May 27. 51 (21):e1-62. [Medline].

26. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008 Jul 8. 118 (2):131-9. [Medline].

27. Beadle R, Williams L. Device therapy in hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2010 Dec. 8 (12):1767-75. [Medline].

28. Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J. 2010 Nov. 74 (11):2271-82. [Medline].

Christina Y Miyake, MD Assistant Professor of Pediatric Cardiology, Texas Children's Hospital

Christina Y Miyake, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, Massachusetts Medical Society, Pediatric and Congenital Electrophysiology Society

Disclosure: Nothing to disclose.

Charles I Berul, MD Professor of Pediatrics and Integrative Systems Biology, George Washington University School of Medicine; Chief, Division of Cardiology, Children's National Medical Center

Charles I Berul, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, Heart Rhythm Society, Pediatric and Congenital Electrophysiology Society, Society for Pediatric Research

Disclosure: Received research grant from: Medtronic.

Syamasundar Rao Patnana, MD Professor of Pediatrics and Medicine, Division of Cardiology, Emeritus Chief of Pediatric Cardiology, University of Texas Medical School at Houston and Children's Memorial Hermann Hospital

Syamasundar Rao Patnana, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, American College of Cardiology, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society for Pediatric Research

Disclosure: Nothing to disclose.

Christopher Johnsrude, MD, MS Chief, Division of Pediatric Cardiology, University of Louisville School of Medicine; Director, Congenital Heart Center, Kosair Children's Hospital

Christopher Johnsrude, MD, MS is a member of the following medical societies: American Academy of Pediatrics and American College of Cardiology

Disclosure: St Jude Medical Honoraria Speaking and teaching

Ameeta Martin, MD Clinical Associate Professor, Department of Pediatric Cardiology, University of Nebraska College of Medicine

Ameeta Martin, MD is a member of the following medical societies: American College of Cardiology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article